Cancer stem cells (CSC) are the culprit responsible for chemotherapy and radiation resistance and cancer progression.CD 133, a member of prominin family was commonly used to isolate CSC of the colon and most other malignancies (Linet al.GCR 2008; Tu et al Curr Stem Cell Ther 2009).High CD133 expression in the tumor or CD133 mRNA in the peripheral blood predicts colon cancer recurrence and poor survival (Horst D BJC 2008; Lin Cancer 2007).Thus, therapy targeting CD133+ colon CSC may improve the clinical outcomes.Integrating capecitabine and celecoxib (XCEL) with or without radiation, we reported unexpectedly high complete response rate 28% (19/66) in patients with unresectable colorectal cancer, (Lin AJCO 2006).Paradoxically, those who did not have surgical resection or had positive margin resections R1-2) experienced had a better paradoxical 3-year relapse free survival of 70% versus 20% (p=0.048) for those with negative margin (R0) resection.